
BriaCell Therapeutics Corp. (BCTX) Stock Ticker
BCTX right now
Market factors today
Unlock the full BCTX picture
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.
BCTX stock facts
| Ticker symbol | BCTX |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $37.5M |
| CEO | William V. Williams |
| Employees | 16 |
| Headquarters | West Vancouver, BC, CA |
| IPO date | 2012-03-14 |
| Website | www.briacell.com |
What you can see for BCTX on Tickr
Live BCTX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the BCTX report.
Rankings
FAQ
What is the ticker symbol for BriaCell Therapeutics Corp.?
The ticker symbol for BriaCell Therapeutics Corp. is BCTX, listed on the NASDAQ Capital Market.
What is BCTX?
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer.…